WuXi PharmaTech, the very successful Shanghai-based contract research organization, has begun construction of a GLP center in Suzhou. The 267,000 square foot facility will house a state-of-the-art preclinical drug safety evaluation center providing toxicology services.  As a stock, WuXi has performed extremely well since its IPO.  More details...

Stock Symbols: (NYSE: WX)